ProfileGDS5678 / 1418831_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 56% 63% 62% 69% 64% 65% 61% 68% 71% 65% 65% 65% 62% 65% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.4620356
GSM967853U87-EV human glioblastoma xenograft - Control 23.7527363
GSM967854U87-EV human glioblastoma xenograft - Control 33.71562
GSM967855U87-EV human glioblastoma xenograft - Control 44.3349569
GSM967856U87-EV human glioblastoma xenograft - Control 53.7853664
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.9729265
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.7332161
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.1768268
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.5251771
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.8788565
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.8725365
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.9291965
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.6916562
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.8799965